Therapeutic Solutions International Announces Positive Clinical Data Using NanoStilbene™ to Stimulate Immune System
August 26 2019 - 9:00AM
InvestorsHub NewsWire
Therapeutic Solutions International Announces Positive
Clinical Data Using NanoStilbene™ to Stimulate Immune System in
Advanced Cancer Patients
Company Submits Results of
Clinical Trial for Publication in Peer Reviewed Medical
Journal
OCEANSIDE, CA --
August 26, 2019 -- InvestorsHub NewsWire
-- Therapeutics
Solutions International, Inc., (OTC
Markets:
TSOI) announced today
positive results from a pilot clinical trial in advanced cancer
patients which have been submitted as a scientific manuscript to a
peer reviewed medical journal.
In the manuscript, 12
advanced cancer patients were treated for 3 weeks with
300mg
daily
administration of
NanoStilbene™.
Immune parameters where assessed before treatment and at
completion. A substantial increase in activity of T cells and
NK cells was observed as a result of treatment.
It is known that NK
cells are the first line of defense against cancer, and that T
cells are the cellular basis for immunological memory which stops
cancer from coming back. Mechanistically, the authors
believed that an
increase
in immune response was the result of immune
suppression
in
cancer-associated
inflammation by NanoStilbene™ [1].
It is known that the active ingredient in NanoStilbene™, called
pterostilbene, is a potent inhibitor of
inflammation.
"There are numerous
cancer therapies whose efficacy is controlled by the activity of
the immune system. Treatments such as radiation therapy, have
now been shown to be actively amplified by a strong immune
system" said Dr. James
Veltmeyer MD, Chief Medical Officer of the Company, and co-author
of the paper. "Furthermore, it has been demonstrated that the
activity of drugs such as the multi-billion dollar a
year
monoclonal antibody Herceptin,
are
dependent
on an intact NK compartment."
The Company is
currently selling NanoStilbene™ as a nutraceutical and is working
with several naturopathic,
allopathic,
integrative, and alternative medicine doctors at
identifying optimum doses and combination with other
drugs.
"There is a trend in
oncology towards providing patients with drugs that not only kill
tumors, but also have a reduced toxicity
profile. Based on my experiences, I believe NanoStilbene™ is
a very promising safe,
non-toxic nutraceutical
adjuvant, and I am proud to
be involved in its scientific development
and evaluation"
said
Thomas
Ichim, Ph.D., Board Member of TSOI and co-author of
paper.
"We are honored to
have such an accomplished team of collaborators that included
Dr.
Santosh Kesari, Senior Author of the submitted paper,
and
Dr. Feng
Lin a distinguished tumor immunologist. To have
scientists of this
caliber work with us at
designing, executing, and now hopefully publishing the
reviewed
results
of this important clinical trial, is the culmination of
four years of work that began with the filing of our issued US
Patent 9,682,047 and the submission of this manuscript on the
23rd
of
August" said Timothy Dixon,
President and CEO of the Company. "Our aim is to have a
world without cancer, and we believe one very
important advancement towards this is the integration of
immunotherapies with other interventions such as our
nanoformulation of pterostilbene."
About Therapeutic Solutions International,
Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is
www.therapeuticsolutionsint.com
and
e-commerce at www.youcanordernow.com.
[1] https://mynanostilbene.com
Safe Harbor
Statement
This release contains
forward-looking statements that are based upon current expectations
or beliefs, as well as a number of assumptions about future events.
Although we believe that the expectations reflected in the
forward-looking statements and the assumptions upon which they are
based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
CONTACT
INFORMATION
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Apr 2023 to Apr 2024